Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP versus R-CHOP plus bortezomib in newly diagnosed diffuse large B-cell lymphoma
2006-003333-33Phase 2Completed
- Sponsor
- Cardiff and Vale University Health Board
- Start
- Jan 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib, rituximab, cyclophosphamide, doxorubicin, vincristine and 1 more in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Cardiff and Vale University Health Board. Primary endpoint: Toxicity. Started Jan 2007; status: completed.
02
Drugs
bortezomibrituximabcyclophosphamidedoxorubicinvincristine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2006-003333-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003333-33.